Bluejay Diagnostics, Inc. filed a Form 8-K on November 4, 2026, disclosing that a 1-for-4 reverse stock split of its common stock became effective at 12:01 a.m. Eastern time on November 3, 2026, following a certificate of amendment filed with the Delaware Secretary of State on October 30, 2026.

Key Highlights

  • Split ratio: The Board selected and approved a 1-for-4 reverse stock split from a range of ratios between 1-for-2 and 1-for-20 that stockholders approved at the June 9, 2026 Annual Meeting.
  • Shares outstanding reduced: Issued and outstanding shares decreased from 4,468,051 to approximately 1,117,013 as a result of the split.
  • Prefunded warrants adjusted: Shares issuable upon exercise of prefunded warrants were reduced from 222,581 to 55,646.
  • Effective date: The Reverse Stock Split became effective as of 12:01 a.m. Eastern time on November 3, 2026, with trading on a post-split basis beginning at market open that day.
  • New CUSIP number: The Company's common stock was assigned a new CUSIP number, 095633707, while the trading symbol "BJDX" remained unchanged.
  • No fractional shares: Stockholders entitled to fractional shares will instead receive a cash payment based on the recent average closing price per share, without interest.
  • Par value and voting rights unchanged: According to the filing, the Reverse Stock Split did not alter the par value of $0.0001 per share or modify any voting rights or other terms of the common stock.

Bluejay Diagnostics 1-for-4 Reverse Split: Share Count, Warrant, and Equity Award Adjustments

According to the Form 8-K filed with the SEC on November 4, 2026, Bluejay Diagnostics, Inc. (NASDAQ:BJDX) completed a reverse stock split of its common stock after its Board of Directors selected a 1-for-4 ratio from a range approved by stockholders at the company's Annual Meeting held on June 9, 2026. The certificate of amendment to the company's Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on October 30, 2026, and the split took effect at 12:01 a.m. Eastern time on November 3, 2026.

The filing disclosed that every four issued and outstanding shares of common stock, par value $0.0001, were converted into one share of common stock, par value $0.0001. This reduced the number of issued and outstanding shares from 4,468,051 to approximately 1,117,013. Concurrently, shares issuable upon the exercise of prefunded warrants were reduced from 222,581 to 55,646. The company's transfer agent, Continental Stock Transfer and Trust Company, is providing instructions to stockholders of record regarding the exchange process, and all post-split shares are being issued in book-entry form through Continental's Direct Registration System.

The filing also stated that proportionate adjustments have been made to the per share exercise price and the number of shares issuable under all outstanding equity awards and warrants, and the number of shares authorized and reserved for issuance under the company's equity incentive plans has been reduced proportionately. No fractional shares are being issued; stockholders otherwise entitled to fractional shares will receive a cash payment based on the recent average closing price per share, which the filing specified "shall not have accrued, and shall be without, interest." The company noted that par value, voting rights, and other terms of the common stock were not modified by the split.

What Was Disclosed

Bluejay Diagnostics reported that a 1-for-4 reverse stock split became effective November 3, 2026, reducing outstanding shares from 4,468,051 to approximately 1,117,013, with proportionate adjustments to warrants and equity awards, and no change to par value or voting rights.